Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -59M | -84M | -104M | -161M | -126M |
| EBITDA | -59M | -84M | 5M | -161M | -126M |
| Net Income | -57M | -80M | -99M | -157M | -126M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$6.73
+1.97% today
1Y Change
+972.01%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Relmada Therapeutics, Inc. (RLMD) is a Healthcare stock with a market cap of $560.00M and listed on NASDAQ. The stock last traded around $6.73 and up 972.0% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +45.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +45.3%, free cash flow +11.5% with operating margin 0.0% and ROIC -67.5%. Stock Foundry combines RLMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RLMD
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RLMD Max Drawdown
-27.44%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RLMD and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$125.8M
+19.9% YoY
Free Cash Flow
-$91.9M
+11.5% YoY
Revenue Growth
+0.0%
EPS Growth
+45.3%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -59M | -84M | -104M | -161M | -126M |
| EBITDA | -59M | -84M | 5M | -161M | -126M |
| Net Income | -57M | -80M | -99M | -157M | -126M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3M | 4M | 4M | 5M | 44M |
| Total Assets | 94M | 46M | 98M | 153M | 223M |
| Total Liabilities | 7M | 10M | 12M | 12M | 15M |
| Shareholder Equity | 87M | 36M | 85M | 140M | 208M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -3M | -4M | -4M | -5M | -44M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
92M
+11.5% YoY
Capital Expenditures
0
Free Cash Flow
92M
+11.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-170.8%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.